

Supporting Information

Mn-Electrocatalytic Oxidative C(sp³)-H Azidation of 2-Oxindoles, β -Keto Esters and Azidation-Cyclization of Trypamines

Shiwen Fan,[‡] Runxia Ma,[‡] Aohua Yang, Hongbo Jia, Yufei Dong, Cheng Guo, and Jingyun Ren*

Shaanxi Key Laboratory for Carbon Neutral Technology; Key Laboratory of Synthetic and Natural Functional Molecule of the Ministry of Education, College of Chemistry & Materials Science, Northwest University, Xi'an 710127, P.R. China.

E-mail: jyrenchem@nwu.edu.cn

[‡] These authors contributed equally to this work.

Table of Contents:


1. General considerations	S2
2. Preparation of substrates.....	S2
3. Optimization of the racemic reaction conditions.....	S3
4. Optimization of the enantioselective reaction conditions.....	S6
5. General procedures and characterization data.....	S7
6. Mechanistic studies.....	S17
7. References.....	S19
8. NMR spectra	S10
9. Chiral HPLC spectra.....	S59
10. X-ray structure of 2a and 4b	S61

1. General considerations

THF were distilled over sodium/benzophenone under N₂ atmosphere. Toluene, Acetonitrile and Dichloromethane were distilled over CaH₂ under N₂ atmosphere. Commercially available materials and other solvents purchased from commercial suppliers were used as received. ¹H and ¹³C NMR spectra were recorded on Bruker-400 (400 MHz) and JEOL ECZ400R (400MHz) spectrometer. Chemical shifts are recorded as δ in units of parts per million (ppm) relative to CDCl₃ (δ : 7.26) for the ¹H NMR and to CDCl₃ (δ : 77.00, the middle peak) the ¹³C NMR measurements. ¹⁹F NMR was performed on a JEOL ECZ400R (400MHz) spectrometer. High resolution mass spectra (HRMS) were obtained on the UltiMate 3000 spectrometer. HRMS were reported in units of mass of charge ratio (*m/z*). Enantiomeric excess values were determined by HPLC analysis on Agress P1100. X-ray crystallography analysis was performed on BrukerSmart APEXIICCD instrument Mo-K α diffractionmeter. Visualization was performed using a UV lamp. Flash chromatography separations were performed on 200-300 mesh silica gel.


Electrodes cleaning procedure: (1) To clean the Pt electrode, immerse it in concentrated nitric acid (~70%) for 5 minutes, followed by rinsing it with deionized water and then acetone. Afterward, dry it in a vacuum drying oven at 40°C; (2) To clean the C electrode, rinse it with deionized water and then acetone, and subsequently, dry it in a vacuum drying oven at 40°C. After that, sand it with sandpaper for additional cleaning. Due to their inexpensiveness, C electrodes are typically disposed of after being used three or four times.

2. Preparation of substrates




Scheme S1 Synthesis of compounds **1**.

Compounds **1** were synthesized via the synthetic routes in scheme S1, according to the literatures known procedures.¹



Scheme S2 Synthesis of compounds **3**.

Compounds **3** were synthesized via the synthetic route in scheme S2, according to the literatures known procedures.²




Scheme S3. Synthesis of compounds **5**.

Compounds **5** were synthesized via the synthetic routes in scheme S3, according to the literatures known procedures.³


3. Optimization of the racemic reaction conditions

Table S1 Optimization of the catalysts and current or voltage^a



Entry	Catalyst	Current I/Voltage V	Yield ^b
1	<i>MnCl</i> ₂ ·4 <i>H</i> ₂ O	12mA	82
2	MnCl ₂ ·4H ₂ O	5mA	64
3	MnCl ₂ ·4H ₂ O	15mA	72
4	MnCl ₂ ·4H ₂ O	2.3 V	67
5	MnCl ₂ ·4H ₂ O	1.5 V	54
6	Mn(OAc) ₂ ·4H ₂ O	12mA	78
7	MnBr ₂	12mA	74
8	MnF ₂	12mA	72
9	CuI	12mA	25
10	FeCl ₃	12mA	trace


^a Standard conditions: graphite plate anode, platinum plate cathode, **1a** (0.2 mmol), NaN₃ (3.0 equiv.), catalyst (5.0 mol%), *n*Bu₄BF₄ (2.0 equiv.), K₂CO₃ (2.0 equiv.), CH₃CN/HFIP (4.0/0.1 mL), current or voltage, room temperature, N₂, 4h, undivided cell. ^b Isolated yield.

Table S2 Optimization of the electrodes and electrolytes^a

Entry	Anode	Cathode	Electrolyte	Yield ^b
1	graphite plate	platinum plate	<i>n</i>Bu₄BF₄	82
2	graphite rod	platinum plate	<i>n</i> Bu ₄ BF ₄	65
3	graphite cloth	platinum plate	<i>n</i> Bu ₄ BF ₄	64
4	RVC	platinum plate	<i>n</i> Bu ₄ BF ₄	62
5	platinum plate	graphite plate	<i>n</i> Bu ₄ BF ₄	trace
6	graphite plate	graphite plate	<i>n</i> Bu ₄ BF ₄	24
7	platinum plate	platinum plate	<i>n</i> Bu ₄ BF ₄	trace
8	graphite plate	platinum plate	<i>n</i> LiClO ₄	74
9	graphite plate	platinum plate	<i>n</i> Bu ₄ NPF ₆	70
10	graphite plate	platinum plate	<i>n</i> Bu ₄ NClO ₄	65
11	graphite plate	platinum plate	<i>n</i> Bu ₄ NBr	15


^a Standard conditions: electrodes, constant current = 12mA ($j = 12 \text{ mA cm}^{-1}$), **1a** (0.2 mmol), NaN₃ (3.0 equiv.), MnCl₂·4H₂O (5.0 mol%), electrolytes (2.0 equiv.), K₂CO₃ (2.0 equiv.), CH₃CN/HFIP (4.0/0.1 mL), room temperature, N₂, 4h, undivided cell. ^b Isolated yield.

Table S3 Optimization of the bases and solvents^a



Entry	Bases	Solvent (4 ml)	H ⁺ source (0.1 ml)	Yield ^b
1	<i>K</i>₂CO₃	<i>CH</i>₃CN	<i>HFIP</i>	82
2	K ₂ CO ₃	CH ₃ CN	HFIP (1ml)	16 (with 2ad in 32%)
3	K ₂ CO ₃	CH ₃ CN	H ₂ O	32 (with 2aa in 15%)
4	K ₂ CO ₃	CH ₃ CN	MeOH	21 (with 2ab in 22%)
5	K ₂ CO ₃	CH ₃ CN	HOAc	25 (with 2ac in 42%)
6	K ₂ CO ₃	DMF	HFIP	26
7	K ₂ CO ₃	DMSO	HFIP	trace
8	K ₂ CO ₃	DCE	HFIP	trace
9	Na ₂ CO ₃	CH ₃ CN	HFIP	68
10	Cs ₂ CO ₃	CH ₃ CN	HFIP	72
11	KHCO ₃	CH ₃ CN	HFIP	75
12	<i>t</i> BuOK	CH ₃ CN	HFIP	64
13	NEt ₃	CH ₃ CN	HFIP	23



^a Standard conditions: graphite plate anode, platinum plate cathode, constant current = 12mA ($j = 12 \text{ mA cm}^{-1}$), **1a** (0.2 mmol), NaN₃ (3.0 equiv.), MnCl₂·4H₂O (5.0 mol%), *n*Bu₄BF₄ (2.0 equiv.), base (2.0 equiv.), solvent/H⁺ source (4.0/0.1 mL), room temperature, N₂, 4h, undivided cell. ^b Isolated yield.

Table S4 Optimization of the azide sources^a

Entry	Azide source	Yield ^b
1	<i>NaN</i> ₃	82
2	TMSN ₃	72
3	TsN ₃	trace
4	Zhdankin reagent	45

^a Standard conditions: graphite plate anode, platinum plate cathode, constant current = 12mA ($j = 12 \text{ mA cm}^{-1}$), **1a** (0.2 mmol), azide source (3.0 equiv.), MnCl₂·4H₂O (5.0 mol%), *n*Bu₄BF₄ (2.0 equiv.), K₂CO₃ (2.0 equiv.), CH₃CN/HFIP (4.0/0.1 mL), room temperature, N₂, 4h, undivided cell. ^b Isolated yield.

4. Optimization of the enantioselective reaction conditions

Table S5 Optimization of the enantioselective reaction conditions^a

^a Standard conditions: graphite plate anode, platinum plate cathode, constant current = 12mA ($j = 12 \text{ mA cm}^{-1}$), **1a** (0.2 mmol), NaN₃ (3.0 equiv.), chiral [Mn] (10.0 mol%), *n*Bu₄BF₄ (2.0 equiv.), K₂CO₃ (2.0 equiv.), CH₃CN /HFIP (4.0/0.1 mL), 0 °C, N₂, 4h, undivided cell. ^b Isolated yield.

5. General procedures characterization data





Fig. S1 Reaction device diagram.


5.1 General procedures of azidation of 2-oxindoles



Inside of an oven-dried 20 mL vial was charged with substrate **1** (0.2 mmol), $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$ (0.01 mmol, 1.9 mg, 0.05 equiv.), Bu_4NBF_4 (0.4 mmol, 131.7 mg, 2.0 equiv.), K_2CO_3 (0.2 mmol, 27.6 mg, 2.0 equiv.), and NaN_3 (0.6 mmol, 39.0 mg, 3.0 equiv.). CH_3CN (4.0 mL) and HFIP (0.1 mL) were added and stirred with a stir bar to form a homogeneous solution. The vial was equipped with graphite plate ($1.0 \times 1.0 \text{ cm}^2$) as anode and platinum plate ($1.0 \times 1.0 \text{ cm}^2$) as cathode with the electric connector under N_2 atmosphere. The vial was stirred and electrolyzed at constant current of 12 mA for 4 hours at room temperature. When the electrolysis was terminated, the mixture was transferred into a separation funnel by ethyl acetate. The combined organic layer was washed with water (10 mL $\times$ 3) and brine, and then dried over with anhydrous Na_2SO_4 . After concentrated under *vacuo*, the crude product was purified by silica gel column chromatography to afford the desired compounds **2**.

CAUTION: NaN_3 is a poisonous and explosive compound. After treatment of the reaction, the aqueous phase was treated with NaClO solution to remove the azide.


5.2. General procedures of azidation of β -keto esters



Inside of an oven-dried 20 mL vial was charged with substrate **3** (0.2 mmol), $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$ (0.01 mmol, 1.9 mg, 0.05 equiv.), Bu_4NBF_4 (0.4 mmol, 131.7 mg, 2.0 equiv.), K_2CO_3 (0.2 mmol, 27.6 mg, 2.0 equiv.), and NaN_3 (0.6 mmol, 39.0 mg, 3.0 equiv.). CH_3CN (4.0 mL) and HFIP (0.1 mL) were added and stirred with a stir bar to form a homogeneous solution. The vial was equipped with graphite plate ($1.0 \times 1.0 \text{ cm}^2$) as anode and platinum plate ($1.0 \times 1.0 \text{ cm}^2$) as cathode with the electric connector under N_2 atmosphere. The vial was stirred and electrolyzed at constant current of 12 mA for 4 hours at room temperature or high temperature. When the electrolysis was terminated, the mixture was transferred into a separation funnel by ethyl acetate. The combined organic layer was washed with water (10 mL $\times$ 3) and brine, and then dried over with anhydrous


Na₂SO₄. After concentrated under *vacuo*, the crude product was purified by silica gel column chromatography to afford the desired compounds **4**.

5.3 General procedures of azidation-cyclization of tryptamines




Inside of an oven-dried 20 mL vial was charged with substrate **5** (0.2 mmol), Mn(OAc)₂ (0.01 mmol, 1.7 mg, 0.05 equiv.), Bu₄NBF₄ (0.4 mmol, 131.7 mg, 2.0 equiv.), K₂CO₃ (0.2 mmol, 27.6 mg, 2.0 equiv.), and NaN₃ (0.6 mmol, 39.0 mg, 3.0 equiv.). CH₃CN (4.0 mL) and HFIP (0.1 mL) were added and stirred with a stir bar to form a homogeneous solution. The vial was equipped with graphite plate (1.0 × 1.0 cm²) as anode and platinum plate (1.0 × 1.0 cm²) as cathode with the electric connector under N₂ atmosphere. The vial was stirred and electrolyzed at constant current of 12 mA for 6 hours at room temperature. When the electrolysis was terminated, the mixture was transferred into a separation funnel by ethyl acetate. The combined organic layer was washed with water (10 mL × 3) and brine, and then dried over with anhydrous Na₂SO₄. After concentrated under *vacuo*, the crude product was purified by silica gel column chromatography to afford the desired compounds **6**.


5.4 Characterization data




3-azido-1-methyl-3-phenylindolin-2-one (2a): Purified by column chromatography (hexane/ethyl acetate = 5:1, R_f = 0.40). Colorless oil (43.2 mg, 82 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.54 – 7.23 (m, 7H), 7.15 (t, *J* = 7.5 Hz, 1H), 6.95 (d, *J* = 7.8 Hz, 1H), 3.27 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 173.5, 143.4, 136.3, 130.3, 128.8 (2×C), 128.8, 128.2, 126.5 (2×C), 125.1, 123.5, 108.9, 69.6, 26.6. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₅H₁₂N₄ONa 287.0903; Found 287.0897.




3-azido-3-(4-methoxyphenyl)-1-methylindolin-2-one (2b): Purified by column chromatography (hexane/ethyl acetate = 4:1, R_f = 0.70). Colorless oil (46.5 mg, 78 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.41 (t, *J* = 7.9 Hz, 1H), 7.39 – 7.35 (m, 2H), 7.33 (d, *J* = 7.3 Hz, 1H), 7.15 (t, *J* = 7.7 Hz, 1H), 6.93 (d, *J* = 7.9 Hz, 1H), 6.91 – 6.87 (m, 2H), 3.79 (s, 3H), 3.25 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 173.5, 143.4, 136.3, 130.3, 128.8 (2×C), 128.8, 128.3, 128.2, 126.5 (2×C), 125.1, 123.5, 108.9, 69.6, 26.6. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₆H₁₄N₄O₂Na 317.1009; Found 317.1021.




3-azido-1-benzyl-3-phenylindolin-2-one (2c): Purified by column chromatography (hexane/ethyl acetate = 4:1, R_f = 0.60). Colorless oil (48.2 mg, 71 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.48 (d, *J* = 7.2 Hz, 2H), 7.41 (q, *J* = 8.2, 7.7 Hz, 3H), 7.36 – 7.26 (m, 7H), 7.12 (t, *J* = 7.5 Hz, 1H), 6.85 (d, *J* = 7.8 Hz, 1H), 5.31 – 4.58 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ: 173.7, 142.5, 136.4, 135.0, 130.2, 128.9 (2×C), 128.8 (2×C), 128.8, 128.4, 127.8 (2×C), 127.2, 126.5 (2×C), 125.1, 123.5, 110.0, 69.8, 44.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₁₆N₄ONa 363.1216; Found 363.1218.



3-azido-1-benzyl-3-(4-fluorophenyl)indolin-2-one (2d): Purified by column chromatography (hexane/ethyl acetate = 4:1, R_f = 0.80). Yellow oil (54.3 mg, 76%). ¹H NMR (400 MHz, CDCl₃) δ: 7.48 – 7.39 (m, 2H), 7.38 – 7.24 (m, 7H), 7.13 (t, *J* = 7.8 Hz, 3H), 7.08 (t, *J* = 8.3 Hz, 1H), 6.84 (d, *J* = 8.3 Hz, 1H), 5.05 – 4.88 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ: 173.5, 164.2, 161.7, 142.5, 135.0, 132.1 (d, *J* = 3.0 Hz), 130.5, 128.9 (2×C), 128.6 (d, *J* = 8.2 Hz), 128.0, 127.9, 127.2 (2×C), 125.2, 123.7, 116.0, 115.8, 110.1, 69.3, 44.2. ¹⁹F NMR (376 MHz, CDCl₃) δ: -112.50. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₁H₁₅FN₄ONa 381.1122; Found 381.1114.




3-azido-1-(4-methoxybenzyl)-3-phenylindolin-2-one (2e): Purified by column chromatography (hexane/ethyl acetate = 4:1, R_f = 0.70). Colorless oil (50.4 mg, 67 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.45 – 7.40 (m, 3H), 7.38 (d, *J* = 7.9 Hz, 2H), 7.29 (t, *J* = 6.9 Hz, 2H), 7.25 (d, *J* = 8.9 Hz, 2H), 7.10 (t, *J* = 7.5 Hz, 1H), 6.86 (d, *J* = 8.6 Hz, 2H), 6.84 (t, *J* = 4.0 Hz, 1H), 4.92 (dd, *J* = 16.0, 24.0 Hz, 2H), 3.78 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 173.7, 159.2, 142.5, 136.4, 130.2, 128.9 (2×C), 128.8, 128.7 (2×C), 128.5, 127.1, 126.5 (2×C), 125.2, 123.5, 114.2 (2×C), 110.0, 69.8, 55.2, 43.7. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₁₈N₄O₂Na 393.1322; Found 393.1316.




3-azido-1-(4-methoxybenzyl)-3-(p-tolyl)indolin-2-one (2f): Purified by column chromatography (hexane/ethyl acetate = 5:1, R_f = 0.80). Colorless oil (55.8 mg, 77 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.34 – 7.16 (m, 8H), 7.09 (t, *J* = 7.4 Hz, 1H), 6.89 – 6.81 (m, 3H), 4.96 – 4.81 (m, 2H), 3.78 (s, 3H), 2.35 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 173.8, 159.2, 142.5, 138.8, 133.4, 130.2, 129.6


(2×C), 128.7 (2×C), 128.6, 127.1, 126.4 (2×C), 125.1, 123.5, 114.2 (2×C), 110.0, 69.7, 55.2, 43.6, 21.1. HRMS (ESI) m/z : $[M+Na]^+$ Calcd for $C_{23}H_{21}N_4O_2$ 385.1659; Found 385.1663.




3-azido-1-(4-methoxybenzyl)-3-(4-methoxyphenyl)indolin-2-one (2g): Purified by column chromatography (hexane/ethyl acetate = 4:1, R_f = 0.60). Colorless oil (67.2 mg, 84 %). 1H NMR (400 MHz, $CDCl_3$) δ : 7.40 – 7.34 (m, 2H), 7.29 (ddd, J = 15.7, 7.8, 1.4 Hz, 2H), 7.23 (d, J = 8.6 Hz, 2H), 7.14–7.06 (m, 1H), 6.94–6.88 (m, 2H), 6.84 (t, J = 8.1 Hz, 3H), 4.99–4.80 (m, 2H), 3.80 (s, 3H), 3.77 (s, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ : 173.8, 159.9, 159.2, 142.5, 130.2, 128.6 (2×C), 128.5, 128.2, 128.0 (2×C), 127.1, 125.1, 123.4, 114.3 (2×C), 114.2 (2×C), 110.0, 69.4, 55.3, 55.2, 43.6. HRMS (ESI) m/z : $[M+Na]^+$ Calcd for $C_{23}H_{20}N_4O_3Na$ 423.1428; Found 423.1436.



1-allyl-3-azido-3-phenylindolin-2-one (2h): Purified by column chromatography (hexane/ethyl acetate = 10:1, R_f = 0.50). Colorless oil (36.4 mg, 62 %). 1H NMR (400 MHz, $CDCl_3$) δ : 7.48 – 7.42 (m, 2H), 7.42 – 7.34 (m, 4H), 7.31 (d, J = 7.3 Hz, 1H), 7.14 (t, J = 7.4 Hz, 1H), 6.94 (d, J = 7.9 Hz, 1H), 5.87 (ddt, J = 17.6, 10.3, 5.2 Hz, 1H), 5.31 – 5.17 (m, 2H), 4.50 – 4.32 (m, 2H). ^{13}C NMR (101 MHz, $CDCl_3$) δ : 173.2, 142.5, 136.3, 130.6, 130.2, 128.8 (2×C), 128.7, 128.2, 126.4 (2×C), 125.1, 123.4, 117.9, 109.8, 69.7, 42.5. HRMS (ESI) m/z : $[M+Na]^+$ Calcd for $C_{17}H_{14}N_4ONa$ 313.1060; Found 313.1065.




3-azido-1,3-diphenylindolin-2-one (2i): Purified by column chromatography (hexane/ethyl acetate = 5:1, R_f = 0.60). Colorless oil (60 mg, 92 %). 1H NMR (400 MHz, $CDCl_3$) δ : 7.55 (d, J = 7.6 Hz, 4H), 7.50 – 7.37 (m, 7H), 7.34 (t, J = 7.9 Hz, 1H), 7.19 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H). ^{13}C NMR (101 MHz, $CDCl_3$) δ : 172.9, 143.3, 136.5, 133.6, 130.2, 129.7 (2×C), 129.0 (2×C), 128.9, 128.5, 128.2, 126.5 (2×C), 126.4 (2×C), 125.4, 124.0, 110.2, 69.7. HRMS (ESI) m/z : $[M+Na]^+$ Calcd for $C_{20}H_{14}N_4ONa$ 349.1060; Found 349.1053.




3-azido-1,3-dimethylindolin-2-one (2j): Purified by column chromatography (hexane/ethyl acetate = 10:1, R_f = 0.40). Colorless oil (21.6 mg, 52 %). 1H NMR (400 MHz, $CDCl_3$) δ : 7.39 – 7.30 (m, 2H), 7.12 (t, J = 7.5 Hz, 1H), 6.87 (d, J = 7.8 Hz, 1H), 3.22 (s, 3H), 1.68 (s, 3H). ^{13}C

NMR (101 MHz, CDCl₃) δ : 174.9, 142.8, 130.1, 128.7, 123.5, 123.3, 108.7, 63.2, 26.4, 21.4. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₁₀H₁₀N₄ONa 225.0747; Found 225.0740.




3-azido-1-benzyl-3-methylindolin-2-one (2k): Purified by column chromatography (hexane/ethyl acetate = 10:1, R_f = 0.40). Colorless oil (56.3 mg, 47 %). ¹H NMR (400 MHz, CDCl₃) δ : 7.37 – 7.30 (m, 3H), 7.28 (d, J = 6.9 Hz, 3H), 7.25 (d, J = 9.9 Hz, 1H), 7.09 (t, J = 7.5 Hz, 1H), 6.75 (d, J = 7.8 Hz, 1H), 4.92 (s, 2H), 1.74 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ : 175.1, 141.9, 135.1, 130.0, 128.9 (2×C), 128.8, 127.8, 127.2 (2×C), 123.6, 123.3, 109.8, 63.4, 43.9, 21.6. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₁₆H₁₄N₄ONa 301.1060; Found 301.1066.




3-azido-1-(4-methoxybenzyl)-3-methylindolin-2-one (2l): Purified by column chromatography (hexane/ethyl acetate = 8:1, R_f = 0.40). Colorless oil (42.3 mg, 68 %). ¹H NMR (400 MHz, CDCl₃) δ : 7.37 (d, J = 8.0 Hz, 1H), 7.25 – 7.18 (m, 3H), 7.16 – 7.06 (m, 2H), 7.03 (d, J = 7.5 Hz, 1H), 6.65 (d, J = 7.8 Hz, 1H), 4.92 (d, J = 1.9 Hz, 2H), 2.39 (s, 3H), 1.77 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ : 175.0, 142.1, 135.7, 132.5, 130.7, 130.0, 128.7, 127.6, 126.3 (2×C), 123.5, 123.3, 110.0, 63.3, 42.1, 21.6, 19.2. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₁₇H₁₆N₄O₂Na 331.1165; Found 331.1162.




3-azido-1-benzhydryl-3-methylindolin-2-one (2m): Purified by column chromatography (hexane/ethyl acetate = 8:1, R_f = 0.40). Colorless oil (40.1 mg, 57 %). ¹H NMR (400 MHz, CDCl₃) δ : 7.44 – 7.20 (m, 11H), 7.10 – 7.01 (m, 2H), 6.99 (s, 1H), 6.52 – 6.40 (m, 1H), 1.73 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ : 175.2, 141.6, 137.2, 136.9, 129.5, 128.7 (2×C), 128.6 (2×C), 128.3 (2×C), 128.2 (2×C), 127.9 (2×C), 127.1, 123.5, 123.1, 112.5, 63.0, 58.5, 21.8. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₂₂H₁₈N₄ONa 377.1371; Found 377.1375.




3-azido-1-(4-chlorobenzyl)-3-ethylindolin-2-one (2n): Purified by column chromatography (hexane/ethyl acetate = 4:1, R_f = 0.50). Colorless oil (40.6 mg, 61 %). ¹H NMR (400 MHz, CDCl₃) δ : 7.31 (dd, J = 8.0, 6.1 Hz, 3H), 7.24 (t, J = 7.8 Hz, 3H), 7.11 (t, J = 7.5 Hz, 1H), 6.72 (d, J = 7.8 Hz, 1H), 4.99 – 4.77 (m, 2H), 2.16 (d, J = 14.1, 7.1 Hz, 2H), 0.79 (t, J = 7.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ : 174.7, 142.6, 138.0, 133.9, 130.1, 129.2 (2×C), 128.8 (2×C), 127.0, 124.2, 123.6, 109.6, 67.5, 43.5, 28.8, 8.1. HRMS (ESI) m/z : [M+Na]⁺ Calcd for C₁₇H₁₅ClN₄ONa 349.0827; Found 349.0830.




3-azido-1,3-dibenzylindolin-2-one (2o): Purified by column chromatography (hexane/ethyl acetate = 10:1, Rf = 0.60). Colorless oil (47.4 mg, 66 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.30 (d, *J* = 7.1 Hz, 1H), 7.24 – 7.05 (m, 8H), 6.95 (d, *J* = 7.7 Hz, 2H), 6.70 (d, *J* = 6.8 Hz, 2H), 6.45 (d, *J* = 7.8 Hz, 1H), 4.75 (m, 2H), 3.43 (s, 2H). ¹³C NMR (101 MHz, CDCl₃) δ: 173.9, 142.7, 134.5, 133.1, 130.5 (2×C), 130.1, 128.7 (2×C), 128.2 (2×C), 127.4, 127.2, 126.6 (2×C), 126.2, 124.5, 123.0, 109.8, 67.7, 43.8, 41.4. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₂H₁₈N₄ONa 377.1371; Found 377.1375.




3-azido-1-(4-methoxybenzyl)-3-(prop-2-yn-1-yl)indolin-2-one (2p): Purified by column chromatography (hexane/ethyl acetate = 6:1, Rf = 0.40). Colorless oil (38.3 mg, 57 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.53 (d, *J* = 7.3 Hz, 1H), 7.33 – 7.18 (m, 3H), 7.11 (t, *J* = 7.6 Hz, 1H), 6.84 (d, *J* = 7.9 Hz, 2H), 6.79 (d, *J* = 7.8 Hz, 1H), 5.06 – 4.67 (m, 2H), 3.77 (s, 3H), 3.14 – 2.70 (m, 2H), 1.95 (d, *J* = 2.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ: 173.2, 159.2, 142.6, 130.5 (2×C), 128.8 (2×C), 127.0, 126.0, 124.4, 123.3, 114.1 (2×C), 109.8, 72.0, 64.8, 55.2, 43.6, 26.3. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₉H₁₆N₄O₂Na 355.1165; Found 355.1165.




3-azido-1-benzhydryl-3-methylindolin-2-one (2q): Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.50). Colorless oil (60.4 mg, 87 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.52 (dd, *J* = 8.3, 2.1 Hz, 1H), 7.40 (d, *J* = 2.5 Hz, 6H), 6.82 (d, *J* = 8.5 Hz, 1H), 3.27 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 173.2, 142.3, 135.7, 133.2 (2×C), 130.4, 129.1 (2×C), 128.3, 126.4 (2×C), 116.1, 110.4, 69.4, 26.8. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₅H₁₁N₄OBrNa 365.0008; Found 365.0013.




3-azido-5-fluoro-1-(4-methoxybenzyl)-3-methylindolin-2-one (2r): Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.80). Colorless oil (44.3 mg, 67 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.20 (d, *J* = 8.7 Hz, 2H), 7.07 (dd, *J* = 7.4, 2.5 Hz, 1H), 6.93 (td, *J* = 8.7, 2.5 Hz, 1H), 6.85 (d, *J* = 8.8 Hz, 2H), 6.68 (dd, *J* = 8.6, 4.1 Hz, 1H), 4.83 (dd, *J* = 2.6 Hz, 2H), 3.77 (s, 3H), 1.71 (s, 3mH). ¹³C NMR (101 MHz, CDCl₃) δ: 175.0, 159.5 (d, *J* = 7.9 Hz), 159.4, 137.9, 130.5 (d, *J* = 7.9 Hz), 128.7 (2×C), 126.9, 116.4 (d, *J* = 23.8 Hz), 114.5 (2×C), 111.9 (d, *J* = 25.0 Hz), 110.7 (d, *J* = 8.0 Hz), 63.4, 55.4, 43.7, 21.7. ¹⁹F NMR (376 MHz, CDCl₃) δ: -118.84. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₇H₁₅FN₄O₂Na 349.1071; Found 349.1066.




3-azido-7-fluoro-1-(4-methoxybenzyl)-3-methylindolin-2-one (2s): Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.80). Brown oil (46.2 mg, 71 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.33 – 7.22 (m, 2H), 7.14 – 7.08 (m, 1H), 7.06 – 7.00 (m, 2H), 6.84 (dd, *J* = 8.4, 1.6 Hz, 2H), 4.98 (s, 2H), 3.77 (s, 3H), 1.69 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 174.8, 159.2, 148.7, 146.3, 131.7 (d, *J* = 2.7 Hz), 129.0, 128.5 (2×C), 124.1 (d, *J* = 6.2 Hz), 119.5 (d, *J* = 3.0 Hz), 118.1 (d, *J* = 20.0 Hz), 114.0 (2×C), 63.2, 55.2, 45.0, 21.7. ¹⁹F NMR (376 MHz, CDCl₃) δ: -132.15. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₇H₁₅FN₄O₂Na 349.1071; Found 349.1068.




tert-butyl 3-azido-5-methyl-2-oxo-3-phenyl-2,3-dihydro-1H-indene-1-carboxylate (2t): Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.40). Yellow oil (63.5 mg, 87 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.86 (dd, *J* = 8.5, 2.8 Hz, 1H), 7.38 (dd, *J* = 7.2, 3.3 Hz, 5H), 7.29 – 7.21 (m, 1H), 7.10 (s, 1H), 2.36 (s, 3H), 1.63 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ: 171.8, 148.8, 137.3, 136.4, 135.2, 131.2, 129.0, 128.9 (2×C), 126.9, 126.7 (2×C), 125.5, 115.5, 85.0, 70.0, 28.0 (3×C), 21.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₂₀N₄O₃Na 387.1428; Found 387.1423.




tert-butyl (R)-3-azido-3-benzyl-2-oxoindoline-1-carboxylate (2u): Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.60). Yellow colorless oil (39.3 mg, 54 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.68 (d, *J* = 8.2 Hz, 1H), 7.31 (td, *J* = 7.8, 1.6 Hz, 1H), 7.21 – 7.12 (m, 4H), 7.12 – 7.05 (m, 1H), 6.95 – 6.85 (m, 2H), 3.44 – 3.12 (m, 2H), 1.59 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ: 173.0, 148.3, 139.5, 132.5, 130.30 (2×C), 130.27, 128.1 (2×C), 127.4, 125.1, 124.6, 124.5, 115.2, 84.77, 67.5, 42.8, 28.0 (3×C). HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₂₀H₂₀N₄O₃Na 387.1428; Found 387.1434.




3-azido-3-phenylindolin-2-one (2v): Purified by column chromatography (hexane/ethyl acetate = 2:1, Rf = 0.60). Colorless oil (28.3 mg, 56 %). ¹H NMR (400 MHz, CDCl₃) δ: 9.38 (s, 1H), 7.47 – 7.43 (m, 2H), 7.42 – 7.36 (m, 3H), 7.32 (d, *J* = 7.8 Hz, 1H), 7.26 (d, *J* = 7.3 Hz, 1H), 7.12 (t, *J* = 7.6 Hz, 1H), 7.00 (d, *J* = 7.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ: 176.4, 140.7, 136.1, 130.5, 128.9 (2×C), 128.9, 128.8, 126.4 (2×C), 125.3, 123.6, 111.2, 70.4. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₄H₁₀F₄ONa 273.0747; Found 273.0751.




methyl 2-azido-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (4a): Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.40). Yellow solid (35.3 mg, 76 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.78 (d, *J* = 7.8 Hz, 1H), 7.66 (t, *J* = 7.5 Hz, 1H), 7.50 – 7.37 (m, 2H), 3.75 (s, 3H), 3.33 (dd, *J* = 258.0, 17.4 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ: 197.2, 168.7, 151.9, 136.4, 132.7, 128.3, 126.3, 125.4, 70.0, 53.3, 38.3. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₁H₁₀O₃Na 254.0536; Found 254.0538.




methyl 2-azido-6-methyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (4b): Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.80). Yellow solid (40.3 mg, 82 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.62 (s, 1H), 7.50 (d, *J* = 8.0 Hz, 1H), 7.35 (d, *J* = 7.9 Hz, 1H), 3.80 (s, 3H), 3.30 (dd, *J* = 252.0, 17.3 Hz, 2H), 2.43 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 197.4, 169.0, 149.4, 138.6, 137.8, 133.1, 126.1, 125.5, 70.5, 53.5, 38.2, 21.1. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₂H₁₁N₃O₃Na 268.0693; Found 268.0700.



methyl 2-azido-6-methoxy-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (4c): Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.40). White solid (46.4 mg, 88 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.34 (d, *J* = 8.5 Hz, 1H), 7.25 (dd, *J* = 8.4, 2.6 Hz, 1H), 7.21 (s, 1H), 3.83 (s, 3H), 3.78 (s, 3H), 3.26 (dd, *J* = 252.3, 17.1 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ: 197.2, 168.9, 160.0, 144.9, 134.1, 127.1, 125.9, 106.3, 70.8, 55.6, 53.4, 37.8. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₂H₁₁N₃O₄Na 284.0642; Found 284.0649.




methyl 2-azido-6-fluoro-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (4d): Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.50). White solid (24.6 mg, 49 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.53 – 7.36 (m, 3H), 3.81 (s, 3H), 3.64 (d, *J* = 17.1 Hz, 1H), 3.01 (d, *J* = 17.2 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ: 196.56 (d, *J* = 2.3 Hz), 162.7 (d, *J* = 250.4 Hz), 134.7 (d, *J* = 8.1 Hz), 127.9 (d, *J* = 7.9 Hz), 124.31 (d, *J* = 23.7 Hz), 124.3 (d, *J* = 23.7 Hz), 111.4 (d, *J* = 22.8 Hz), 70.8, 53.6, 38.0. ¹⁹F NMR (376 MHz, CDCl₃) δ: -112.29. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₁H₈FN₃O₃Na 272.0442; Found 272.0443.




methyl 2-azido-6-chloro-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (4e): Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.80). White solid (32.3 mg, 61 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.75 (d, *J* = 8.0 Hz, 1H), 7.47 (d, *J* = 1.8 Hz, 1H), 7.43 (dd, *J* = 7.9, 1.8 Hz,


1H), 3.80 (s, 3H), 3.32 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ: 196.0, 168.5, 153.4, 143.2, 131.3, 129.3, 126.7, 126.6, 70.1, 53.6, 38.1. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₁H₈ClN₃O₃Na 288.0146; Found 288.0152.




methyl 2-azido-5-methyl-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (4f): Purified by column chromatography (hexane/ethyl acetate = 8:1, R_f = 0.40). Colorless oil (38.7 mg, 78 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.69 (d, *J* = 7.8 Hz, 1H), 7.25 (d, *J* = 8.4 Hz, 2H), 3.78 (s, 3H), 3.29 (dd, *J* = 256.9, 17.4 Hz, 2H), 2.46 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ: 196.6, 169.0, 152.5, 148.2, 130.5, 129.7, 126.7, 125.3, 70.3, 53.4, 38.2, 22.1. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₂H₁₁N₃O₃Na 268.0693; Found 268.0688.




methyl 2-azido-5-bromo-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (4g): Purified by column chromatography (hexane/ethyl acetate = 4:1, R_f = 0.40). White solid (28.3 mg, 46 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.72 – 7.65 (m, 2H), 7.60 (dd, *J* = 8.2, 1.5 Hz, 1H), 3.81 (s, 3H), 3.65 (d, *J* = 17.4 Hz, 1H), 3.02 (d, *J* = 17.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ: 196.0, 168.5, 153.4, 143.2, 131.3, 129.3, 126.7, 126.6, 70.1, 53.6, 38.1. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₁H₈BrN₃O₃Na 331.9641; Found 331.9635.



methyl 2-azido-5,6-dimethoxy-1-oxo-2,3-dihydro-1H-indene-2-carboxylate (4h): Purified by column chromatography (hexane/ethyl acetate = 2:1, R_f = 0.40). White solid (44.7 mg, 76 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.18 (s, 1H), 6.86 (s, 1H), 3.97 (s, 3H), 3.90 (s, 3H), 3.79 (s, 3H), 3.24 (dd, *J* = 255.3, 17.1 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃) δ: 195.5, 169.2, 156.9, 150.1, 147.9, 125.5, 107.1, 105.3, 70.5, 56.4, 56.1, 53.4, 38.2. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₃H₁₃N₃O₅Na 314.0747; Found 314.0753.




methyl 2-azido-1-oxo-1,2,3,4-tetrahydronaphthalene-2-carboxylate (4i): Purified by column chromatography (hexane/ethyl acetate = 10:1, R_f = 0.40). Colorless oil (25.6 mg, 52 %). ¹H NMR (400 MHz, CDCl₃) δ: 8.01 (d, *J* = 7.9 Hz, 1H), 7.50 (t, *J* = 7.3 Hz, 1H), 7.30 (t, *J* = 7.6 Hz, 1H), 7.22 (d, *J* = 7.6 Hz, 1H), 3.78 (s, 3H), 3.07 (ddd, *J* = 17.4, 9.7, 4.7 Hz, 1H), 2.88 (dt, *J* = 17.1, 5.2 Hz, 1H), 2.56 (ddd, *J* = 14.1, 9.5, 4.6 Hz, 1H), 2.16 (dt, *J* = 13.9, 5.3 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ: 189.1, 168.8, 143.3, 134.4, 129.5, 128.6, 128.2, 127.0, 70.7, 53.0, 31.1, 24.4. HRMS (ESI) m/z: [M+Na]⁺ Calcd for C₁₂H₁₁N₃O₃Na 268.0693; Found 268.0694.




tert-butyl 3a-azido-8-tosyl-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (6a):

Purified by column chromatography (hexane/ethyl acetate = 6:1, Rf = 0.40). White solid (58.3 mg, dr = 1.8:1, 64 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.76 (d, *J* = 8.1 Hz, 3.7H), 7.67 (d, *J* = 7.9 Hz, 3.6H), 7.61 (d, *J* = 8.3 Hz, 1H), 7.44 (ddd, *J* = 8.2, 5.6, 2.9 Hz, 2H), 7.39 – 7.32 (m, 1H), 7.28 (d, *J* = 8.5 Hz, 2H), 7.21 (d, *J* = 8.3 Hz, 3.7H), 7.18 (s, 3.9H), 7.15 (d, *J* = 8.4 Hz, 2H), 5.55 (s, 1H), 5.39 (s, 1.8H), 3.48 – 3.19 (m, 3.7H), 3.18 – 2.92 (m, 2H), 2.37 (s, 3.7H), 2.33 (s, 5.5H), 2.08 (s, 3H), 2.03 (s, 2H), 1.45 (s, 16.2H), 1.44 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ: 155.9, 155.8, 145.3, 145.1, 140.0, 139.1, 135.0, 134.4, 131.7, 130.9, 130.2 (2×C), 130.0 (3.6×C), 129.8, 129.7, 127.4 (3.6×C), 127.3 (2×C), 125.3, 125.2, 124.4, 123.8, 116.9, 115.8, 84.4, 83.7, 79.6, 79.5, 72.2, 72.1, 38.7, 36.5, 35.6, 31.9, 28.5, 28.3, 21.7 (3×C), 21.6 (5.4×C). HRMS (ESI) *m/z*: [M+H]⁺ Calcd for C₂₂H₂₆N₅O₄S 456.1700; Found 456.1708.



tert-butyl 3a-azido-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (6b):

Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.40). Colorless oil (21.1 mg, dr = 1:1, 35 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.26 (t, *J* = 4.0 Hz, 2H), 7.21 (dd, *J* = 7.9, 2.7 Hz, 2H), 6.85 (q, *J* = 7.8 Hz, 2H), 6.70 (d, *J* = 7.9 Hz, 2H), 5.31 (s, 1H), 5.24 (s, 1H), 5.18 (s, 0.94H), 4.72 (s, 0.80H), 3.71 (dt, *J* = 48.2, 9.3 Hz, 2H), 3.09 (dtd, *J* = 14.7, 10.6, 6.2 Hz, 2H), 2.41 (dt, *J* = 9.3, 4.9 Hz, 2H), 2.37 – 2.28 (m, 2H), 1.53 (s, 9H), 1.45 (s, 9H). ¹³C NMR (101 MHz, CDCl₃) δ: 154.4, 153.4, 150.0, 149.7, 131.1, 131.0, 125.2, 125.1, 124.0, 123.9, 119.8, 119.4, 110.5, 110.4, 80.9, 80.6, 80.5, 77.3, 76.4, 45.8, 45.4, 35.2, 35.0, 28.7 (3×C), 28.5 (3×C). HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₅H₁₉N₅O₂Na 324.1431; Found 324.1426.




ethyl 3a-azido-3,3a,8,8a-tetrahydropyrrolo[2,3-b]indole-1(2H)-carboxylate (6c):


Purified by column chromatography (hexane/ethyl acetate = 4:1, Rf = 0.40). Colorless oil (21.3 mg, dr = 1.4:1, 39 %). ¹H NMR (400 MHz, CDCl₃) δ: 7.27 (d, *J* = 4.1 Hz, 2.8H), 7.24 (d, *J* = 9.6 Hz, 2.8H), 6.86 (q, *J* = 6.9 Hz, 2H), 6.70 (d, *J* = 7.9 Hz, 2H), 5.34 (s, 1.3H), 5.31 (s, 1.0H), 5.21 (s, 1.2H), 4.79 (s, 0.8H), 4.22 (dd, *J* = 7.1, 3.8 Hz, 2H), 4.14 (dd, 2.9H), 3.81 (t, *J* = 9.5 Hz, 1.0H), 3.71 (t, *J* = 9.6 Hz, 1.4H), 3.19 – 3.13 (m, 1.0H), 3.11 (dd, *J* = 7.4, 3.3 Hz, 1.4H), 2.43 (q, *J* = 7.5 Hz, 2.8H), 2.40 – 2.26 (m, 2.0H), 1.34 (t, *J* = 7.1 Hz, 3.0H), 1.26 (t, *J* = 5.7 Hz, 4.4H). ¹³C NMR (101 MHz, CDCl₃) δ: 171.1, 155.1, 149.8, 131.0, 131.0, 124.9, 123.8, 123.7, 119.7, 119.4, 110.4, 110.3, 80.7, 80.3, 76.2, 61.6, 61.4, 60.4, 45.7, 45.5, 35.1, 35.0, 29.7, 21.0, 14.8, 14.2. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₁₃H₁₅N₅O₂Na 296.1118; Found 296.1122.

6. Mechanism studies

6.1 Radical trapping experiment



Inside of an oven-dried 20 mL vial was charged with substrate **5** (0.2 mmol), Mn(OAc)₂ (0.01 mmol, 1.7 mg, 0.05 equiv.), Bu₄NBF₄ (0.4 mmol, 131.7 mg, 2.0 equiv.), K₂CO₃ (0.2 mmol, 27.6 mg, 2.0 equiv.), NaN₃ (0.6 mmol, 39.0 mg, 3.0 equiv.), and TEMPO or BHT (0.4 mmol, 2.0 equiv.). CH₃CN (4.0 mL) and HFIP (0.1 mL) were added and stirred with a stir bar to form a homogeneous solution. The vial was equipped with graphite plate (1.0 × 1.0 cm²) as anode and platinum plate (1.0 × 1.0 cm²) as cathode with the electric connector under N₂ atmosphere. The vial was stirred and electrolyzed at constant current of 12 mA for 6 hours at room temperature. When the electrolysis was terminated, the mixture was transferred into a separation funnel by ethyl acetate. The combined organic layer was washed with water (10 mL × 3) and brine, and then dried over with anhydrous Na₂SO₄. After concentrated under *vacuo*, the crude product was purified by silica gel column chromatography to afford the desired compounds **2a**, or **2ab**.



3-(3,5-di-tert-butyl-4-hydroxybenzyl)-1-methyl-3-phenylindolin-2-one (2ab): Purified by column chromatography (hexane/ethyl acetate = 4:1, R_f = 0.70). Yellow solid (82 mg, 76%). ¹H NMR (400 MHz, CDCl₃) δ: 7.54 (d, *J* = 7.6 Hz, 2H), 7.35 (t, *J* = 7.4 Hz, 2H), 7.31 – 7.26 (m, 1H), 7.25 – 7.18 (m, 2H), 7.10 (t, *J* = 7.5 Hz, 1H), 6.61 (s, 2H), 6.58 (d, *J* = 8.1 Hz, 1H), 4.97 (s, 1H), 3.49 (m, 2H), 2.91 (s, 3H), 1.27 (s, 18H). ¹³C NMR (101 MHz, CDCl₃) δ: 177.8, 152.3, 143.8, 139.5, 134.6 (2×C), 131.6, 128.4 (2×C), 127.9, 127.4 (2×C), 127.2, 126.7 (2×C), 125.8, 125.5, 121.9, 107.7, 58.7, 44.4, 34.0 (2×C), 30.2 (6×C), 25.9. HRMS (ESI) *m/z*: [M+Na]⁺ Calcd for C₃₀H₃₅NO₂Na 564.2560; Found 564.2560.

6.2 CV experiments

CV experiments was recorded on the CHI 660E instrument. A 3 mm diameter glassy carbon disc electrode was used as the working electrode; a platinum plated electrode was used as the counter electrode; a Ag/AgCl was used as reference electrode. The working temperature was 298 K. All solutions were degassed via freeze-pump-thaw method prior to use and nitrogen was bubbled through the solutions for at least 5 min before the experiment was performed. A CH₃CN solution (5.0 mL) of sample including 10 mM of each sample and 0.1 M of *n*Bu₄BF₄ was prepared as an electrochemical solution. The spectra were recorded with the scan rate of 100 mVs⁻¹ or 200 mVs⁻¹. For ease of testing, we selected more soluble Mn(OTf)₂ and *n*Bu₄N₃ as the catalyst and azide source.




Fig. S2 CV (Cyclic voltammetry) experiments

6.3 Proposed mechanisms of the successful azidation-cyclization of tryptamines and the unsuccessful azidation-cyclization of tryptophols





Fig. S3 Proposed mechanisms of azidation-cyclization of tryptamines and tryptophols

We proposed a mechanism, as illustrated in Figure S3, to explain why tryptamines could undergo azidation-cyclization while tryptophols could not. Initially, the Mn(II)-N₃ species was oxidized to Mn(III)-N₃ at the anode, which then underwent a HAT process with substrate **A**, generating N radical **B**. Subsequently, N radical **B** participated in a radical cyclization, forming carbon radical **C**. Following this step, the Mn(III)-N₃ transferred a azidyl radical to **C**, leading to the production of the final product 3a-azido-pyrroloindoline **D**. However, the alkyl OH groups of tryptophols faced challenges in forming O radicals **F** through HAT under our electrocatalytic conditions, leading to side reactions.


7. References

1. (a) R. He, C. Ding and K. Maruoka, Phosphonium Salts as Chiral Phase-Transfer Catalysts: Asymmetric Michael and Mannich Reactions of 3-Aryloxindoles, *Angew. Chem. Int. Ed.*, 2009, **48**, 4559; (b) L. Zong, S. Du, K. F. Chin, C. Wang and C.-H. Tan, Enantioselective Synthesis of Quaternary Carbon Stereocenters: Addition of 3-Substituted Oxindoles to Vinyl Sulfone Catalyzed by Pentanidiums, *Angew. Chem. Int. Ed.*, 2015, **54**, 9390; (c) S. Liu, K. Maruoka and S. Shirakawa, Chiral Tertiary Sulfonium Salts as Effective Catalysts for Asymmetric Base-Free Neutral Phase-Transfer Reactions, *Angew. Chem. Int. Ed.*, 2017, **56**, 4819.
2. (a) Q.-H. Deng, T. Bleith, H. Wadepohl and L. H. Gade, Enantioselective Iron-Catalyzed Azidation of β -Keto Esters and Oxindoles, *J. Am. Chem. Soc.*, 2013, **135**, 5356; (b) M. V. Vita and J. Waser, Azidation of β -Keto Esters and Silyl Enol Ethers with a Benziodoxole Reagent, *Org. Lett.*, 2013, **15**, 3246; (c) A. Yanagisawa, K. Takagi, M. Horiguchi, K. Dezaki, T. Marui, E. Saito, T. Ebihara, G. M. Russell, T. Watanabe and K. Midorikawa, Asymmetric α -Azidation Reaction of β -Ketoesters Catalyzed by Chiral Tin Alkoxides, *Asian J. Org. Chem.*, 2023, **12**.
3. (a) J. Xu and R. Tong, An Environmentally Friendly Protocol for Oxidative Halocyclization of Tryptamine and Tryptophol Derivatives, *Green Chem.*, 2017, **19**, 2952; (b) J. C. Yi, C. Liu, L. X. Dai and S. L. You, Synthesis of C3-Methyl-Substituted Pyrroloindolines and Furoindolines Via Cascade Dearomatization of Indole Derivatives with Methyl Iodide, *Chem. Asian J.*, 2017, **12**, 2975.


8. NMR spectra




^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)




^{19}F NMR (376MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)




^{19}F NMR (376MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)




^{19}F NMR (376MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)




^{19}F NMR (376MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)







^1H NMR (400MHz, CDCl_3)




^{13}C NMR (101MHz, CDCl_3)



9. Chiral HPLC spectra




Enantiomeric excess was determined by chiral HPLC: Chiralcel IA (Hex/IPA = 99/1, 1.0 mL/min, 254 nm, 25°C), 20.08 min (major), 28.61 min, 34% *ee*.




结果表(FSW44022022_07_16 21_35_55)

序号	保留时间 [min]	峰高[mAU]	峰高[%]	峰面积 [mAU.s]	峰面积[%]	0.05峰高外峰 宽[min]	化合物名称
1	20.431	647.073	66.3	34741.121	50.4	1.792	
2	28.070	328.155	33.7	34208.669	49.6	3.494	
合计		975.228	100.0	68949.790	100.0		




结果表(FSW44012022_07_16 20_57_07)

序号	保留时间 [min]	峰高[mAU]	峰高[%]	峰面积 [mAU.s]	峰面积[%]	0.05峰高外峰 宽[min]	化合物名称
1	20.081	744.079	76.5	46569.131	67.0	2.060	
2	28.606	228.603	23.5	22928.931	33.0	3.247	
合计		972.682	100.0	69498.062	100.0		




Enantiomeric excess was determined by chiral HPLC: Chiralcel IA (Hex/IPA = 99/1, 1.0 mL/min, 254 nm, 25°C), 18.57 min, 21.61 min (major), 43% *ee*.



结果表(FSW413912022_10_21_16_34_34)


序号	保留时间 [min]	峰高[mAU]	峰高[%]	峰面积 [mAU.s]	峰面积[%]	0.05峰高外峰 宽[min]	化合物名称
1	18.456	1074.291	56.4	26319.115	49.9	0.850	
2	21.893	832.071	43.6	26380.189	50.1	1.104	
合计		1906.362	100.0	52699.304	100.0		



结果表(FSW4140)


序号	保留时间 [min]	峰高[mAU]	峰高[%]	峰面积 [mAU.s]	峰面积[%]	0.05峰高外峰 宽[min]	化合物名称
1	18.565	2014.851	43.5	56639.203	28.5	0.960	
2	21.613	2621.066	56.5	142307.576	71.5	1.763	
合计		4635.917	100.0	198946.779	100.0		

10. X-ray structure of 2a and 4b.



The supplementary crystallographic data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Bond precision:	C-C = 0.0200 Å	Wavelength=1.34139
Cell:	a=13.2924 (12) alpha=90	b=43.711 (4) beta=98.601 (4)
Temperature:	260 K	c=9.1248 (8) gamma=90
	Calculated	Reported
Volume	5242.1 (8)	5242.1 (8)
Space group	C c	C c
Hall group	C -2yc	C -2yc
Moiety formula	C15 H12 N4 O	?
Sum formula	C15 H12 N4 O	C15 H12 N4 O
Mr	264.29	264.29
Dx, g cm ⁻³	1.339	1.339
Z	16	16
Mu (mm ⁻¹)	0.457	0.457
F000	2208.0	2208.0
F000'	2212.90	
h, k, lmax	15, 52, 10	15, 52, 10
Nref	9330 [4678]	7549
Tmin, Tmax	0.872, 0.892	0.308, 0.705
Tmin'	0.872	
Correction method= # Reported T Limits: Tmin=0.308 Tmax=0.705		
AbsCorr = MULTISCAN		
Data completeness=	1.61/0.81	Theta(max)= 53.199
R(reflections)=	0.1215 (5027)	wR2(reflections)=
S =	1.167	0.3051 (7549)
	Npar= 720	



The supplementary crystallographic data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Bond precision:	C-C = 0.0116 Å	Wavelength=1.34139
Cell:	a=7.753 (4) alpha=87.788 (19)	b=11.904 (6) beta=81.71 (3)
Temperature:	150 K	c=12.899 (6) gamma=86.87 (2)
Volume	Calculated 1175.7 (10)	Reported 1175.6 (11)
Space group	P -1	P -1
Hall group	-P 1	-P 1
Moiety formula	C12 H11 N3 O3	C12 H11 N3 O3
Sum formula	C12 H11 N3 O3	C12 H11 N3 O3
Mr	245.24	245.24
Dx, g cm ⁻³	1.385	1.386
Z	4	4
Mu (mm ⁻¹)	0.545	0.549
F000	512.0	512.0
F000'	513.30	
h, k, lmax	9, 14, 15	0, 0, 0
Nref	4257	4105
Tmin, Tmax	0.896, 0.921	
Tmin'	0.896	
Correction method=	Not given	
Data completeness=	0.964	Theta(max)= 53.559
R(reflections)=	0.1492 (1766)	wR2(reflections)=
S =	1.060	0.3297 (4105)
	Npar= 323	
